Closed Loop Glucose Control in Intensive Care Unit

Stress Hyperglycaemia Clinical Trial

— CLASSIC  

Official title:

An Open-label, Single-centre, Randomised Controlled Trial to Assess the Safety and Efficacy of Automated Closed-loop Blood Glucose Control in Comparison With Standard Care in Adults in Intensive Care Unit

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01440842
• Other study ID #: CLASSIC 01
• Status: Completed
• Phase: Phase 2
• First received: September 22, 2011
• Last updated: December 31, 2012
• Start date: May 2012
• Est. completion date: October 2012

Study information

• Verified date: December 2012
• Source: University of Cambridge
• Contact: n/a
• Is FDA regulated: No
• Health authority: United Kingdom: Research & Development Department, Cambridge University Hospitals NHS Foundation Trust, Box 277, Addenbrookes Hospital, Hills Road, Cambridge Cb2 0QQ AND Research Office, Univerity of Cambridge, Box 111,Addenbrookes Hospital, Hills Road,
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to assess the efficacy, safety and feasibility of a computer-based control algorithm to control glucose levels in adults in intensive care unit, in comparison to standard care.

Description:

This will be a single centre, open-label, randomised, parallel design, feasibility study conducted at Neurosciences Critical Care Unit (NCCU), Addenbrooke's hospital, Cambridge, UK. Study will aim for 24 adult subjects (12 participants in each arm of the trial) and study will last for up to 49 hours in each subject. Subjects will have a commercially available Conformité Européenne(CE) marked subcutaneous glucose sensor inserted at the start of the study. Glucose data from the sensor will be transmitted to a small bedside tablet computer, containing the algorithm which will determine insulin infusion rates aimed at maintaining glucose level between 6.0 - 8.0 mmol/L. The advice from the algorithm will be sent to the infusion pump via USB cable and insulin will be delivered intravenously. The system will also deliver intravenous glucose via a second infusion pump at times of low glucose levels. Samples for reference glucose values will be obtained either from an arterial line or central venous cannula and will be analysed using standard blood gas analyser in real time. Subjects randomised to standard care will receive intravenous insulin based on current treatment guidelines at the Neurosciences critical care unit (NCCU), Addenbrooke's Hospital, Cambridge, UK.

The primary outcome is time spent in target glucose range between 6.0 to 8.0 mmol/L as recorded by reference glucose. Secondary outcomes are the time spent with glucose levels above and below target, as recorded by reference glucose, and sensor accuracy. Safety includes evaluation of significant hypoglycaemia and hyperglycaemia and other adverse events.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 24
• Est. completion date: October 2012
• Est. primary completion date: October 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Aged 18 years and older

• Admitted to Neurosciences critical care unit; (all patients are eligible regardless of admitting diagnosis except where specified under exclusion criteria)

• Stay in intensive care unit expected to be at least 48 hours

• At least one of the following conditions applies:

• Not on insulin infusion and single confirmed reference blood glucose level > 10.0 mmol/l

• Already on insulin infusion including those subjects with pre-existing diabetes.

Exclusion Criteria:

• Patients with diabetic ketoacidosis or hyperosmolar hyperglycaemic non-ketotic coma (HONK)

• Patients who are receiving therapeutic hypothermia

• Known or suspected allergy to insulin

• Any disease or condition which the investigator or treating physician feels would interfere with the trial or the safety of the patient (i.e. liver failure, other fatal organ failures)

• Patients with significant abnormalities of blood clotting.

• Moribund patients likely to die within 48 hours

• Pregnancy

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Hyperglycemia
• Stress Hyperglycaemia

Intervention

Other:
• Closed-loop insulin delivery
Intravenous infusion delivery of Actrapid insulin and dextrose, dose calculated by Model Predictive Control (MPC) algorithm, based on continuous glucose sensor readings.
• Standard IV insulin infusion sliding scale
Standard intravenous insulin infusion sliding scale as per intensive care unit protocol.

Locations

Country	Name	City	State
United Kingdom	Cambridge University Hospitals NHS Foundation Trust, Addenbrookes Hospital	Cambridge	Cambridgeshire

Sponsors (3)

Lead Sponsor	Collaborator
University of Cambridge	Cambridge University Hospitals NHS Foundation Trust, European Commission

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of glucose values in target range (6.0 - 8.0 mmol/l) as recorded by reference glucose measurements.	Definition of Reference glucose = Blood Glucose level measured by arterial blood gas analyzer.; During the study subjects will have the reference glucose measured every 1 hour and this is used for the calculation percentage glucose values.	Up to 49 hours in each subject.	No
Secondary	Percentage of glucose values in range (4.0 - 10.0 mmol/l) as recorded by reference glucose measurements.	Definition of Reference glucose = Blood Glucose level measured by arterial blood gas analyzer.; During the study subjects will have the reference glucose measured every 1 hour and this is used for the calculation percentage glucose values.	Up to 49 hours in each subject	No
Secondary	Percentage of glucose values <4.0 mmol/l and >8.0 mmol/l as recorded by reference glucose measurements.	Definition of Reference glucose = Blood Glucose level measured by arterial blood gas analyzer.; During the study subjects will have the reference glucose measured every 1 hour and this is used for the calculation percentage glucose values.	Up to 49 hours in each subject.	No
Secondary	Percentage of glucose values > 10.0 mmol/l as recorded by reference glucose measurements.	Definition of Reference glucose = Blood Glucose level measured by arterial blood gas analyzer.; During the study subjects will have the reference glucose measured every 1 hour and this is used for the calculation percentage glucose values.	Up to 49 hours in each subject,	No
Secondary	Mean and standard deviation of reference glucose measured using arterial blood gas analyzer	Definition of Reference glucose = Blood Glucose level measured by arterial blood gas analyzer. This is reported in mmol/L; During the study subjects will have the reference glucose measured every 1 hour and this is used for the calculation of mean (mmol/L) and standard deviation which will reflect the efficasy of closed loop insulin delivery.	Up to 49 hours in each subject.	No
Secondary	Mean and median absolute and relative difference between matched pairs of subcutaneous glucose sensor and reference plasma glucose.	For a given subcutaneous glucose sensor value, difference between the sensor and the reference glucose will be calculated. Example - Reference glucose 10 mmol/L and sensor glucose 12 mmol/L, therefore absolute difference will be 2 mmol/L. Mean and median of these deviations will be reported in mmol/L. The term relative implies that data has been converted to a percentage deviation from reference glucose.	Up to 49 hours in each subject.	No
Secondary	Time to reach target glucose		Up to 49 hours in each subject.	No
Secondary	Insulin infusion rates		Up to 49 hours in each subject.	No
Secondary	Frequency and magnitude of significant hypoglycaemic (< 3.0 mmol/L), severe hypoglycaemic (<2.0 mmol/L) and significant hyperglycaemic (> 15mmol/l) episodes.		Up to 49 hours in each subject.	Yes